CORRECTION article

Front. Mol. Biosci., 30 August 2021

Sec. Molecular Diagnostics and Therapeutics

Volume 8 - 2021 | https://doi.org/10.3389/fmolb.2021.727969

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib

  • 1. Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China

  • 2. Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China

  • 3. Shanghai Institution of Medical Imaging, Shanghai, China

  • 4. National Clinical Research Center for Interventional Medicine, Shanghai, China

  • 5. Institute of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen, China

  • 6. Department of Radiology, The Affiliated People’s Hospital of Ningbo University, Ningbo, China

In the published article, there was an error regarding the affiliations for Lei Zhang and Cai-Fang Ni. One of the affiliations was added in error. This has now been removed.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

TACE, sorafenib, HCC, platelet count, neutrophils, lymphocytes

Citation

Zhang L, Yan Z-P, Hou Z-H, Huang P, Yang M-J, Zhang S, Zhang S, Zhang S-H, Zhu X-L, Ni C-F and Li Q (2021) Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib. Front. Mol. Biosci. 8:727969. doi: 10.3389/fmolb.2021.727969

Received

20 June 2021

Accepted

30 July 2021

Published

30 August 2021

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

8 - 2021

Updates

Copyright

*Correspondence: Qiang Li,

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally

This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics